

ASX ANNOUNCEMENT

5 July 2022

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

Between 30 June 2022 and 4 July 2022, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued 5,209 new fully paid Ordinary Shares (**New Shares**) to investors raising \$57,091. The issue of New Shares is as a result of the conversion of 3,334 unlisted Options exercisable at \$11.50 each and 1,875 unlisted Options exercisable at \$10.00 each.

Details of the securities issued

Class of securities:	Fully paid Ordinary Shares
ASX code:	AVR
Date of the issue:	30 June 2022 and 4 July 2022
Total number of securities issued:	5,209

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the New Ordinary Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>